Skip to main content
Premium Trial:

Request an Annual Quote

Celera Added to Nasdaq Biotech Index; Decode, Orchid Bounced

NEW YORK (GenomeWeb News) – Nasdaq announced that it has completed its semi-annual ranking of the Nasdaq Biotechnology Index, and as a result Celera will be added to the index as of the opening of trade on Nov. 24.
 
While Celera was added, Decode Genetics and Orchid Cellmark have been dropped from the index.
 
The Nasdaq Biotech Index is ranked on a semi-annual basis in May and September. Firms must meet certain classification criteria and must be listed on the Nasdaq Global Market or Nasdaq Global Select Market. They also must meet minimum requirements for market value, average daily share volume, and seasoning as a public company.

The Scan

Dropped Charges

The US Justice Department has dropped visa fraud charges against five Chinese researchers, according to the Wall Street Journal.

More Kids

The Associated Press says Moderna is expanding its SARS-CoV-2 vaccine study to included additional children and may include even younger children.

PNAS Papers on Rat Clues to Human Migration, Thyroid Cancer, PolyG-DS

In PNAS this week: ancient rat genome analysis gives hints to human migrations, WDR77 gene mutations in thyroid cancer, and more.

Purnell Choppin Dies

Purnell Choppin, a virologist who led the Howard Hughes Medical Institute, has died at 91, according to the Washington Post.